SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors react to a post-earnings rally fueled by a strong ad revenue recovery and growth in Snapchat+ subscribers, even as persistent concerns regarding insider share sales and ongoing legal challenges weigh on sentiment. The community is actively debating whether the stock's recent performance represents a structural turnaround or a temporary relief bounce, with many closely watching for upcoming developments in the company's AR hardware strategy.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on the upcoming June 17 Investor Day, with widespread speculation regarding a potential buyout and the company's timeline for an NDA submission for its wet AMD treatment, AXPAXLI. Community discussion is heavily divided between bullish sentiment regarding the product's market potential and bearish concerns about trial design requirements, share dilution, and the company's path to regulatory approval.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is seeing heightened investor attention following a mixed earnings report and ongoing discussions regarding its competitive positioning in the wet AMD market against rival TKI-based therapies. While some community members express concern over trial design and potential dilution, bulls remain focused on the company's clinical pipeline as a major binary catalyst.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris Technologies is attracting significant investor attention following the announcement of a proposed $1 billion Department of Defense investment to expand its missile production capacity and the planned spin-off of its Missile Solutions unit into a standalone company. The community is actively discussing the potential value creation of this IPO and how the move aligns the company with increased government spending on defense and aerospace technologies.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as market participants weigh strong AI-driven cloud growth and the potential IPO of its AI-chip unit against broader concerns regarding the Chinese tech sector's regulatory and macro headwinds. The community remains deeply divided, with some investors accumulating positions on a deep-value thesis while others view the stock as a long-term trap fueled by geopolitical uncertainty.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is currently navigating broader market volatility fueled by persistent geopolitical tensions in the Strait of Hormuz and a cooling U.S. labor market. Investors are closely scrutinizing this week's key CPI and PPI inflation reports to gauge the Fed's next steps, while sentiment remains split between optimism over corporate earnings and concerns regarding extended market valuations.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty Industries is trending as investors monitor the company's progress in ramping up its Sangdong tungsten mine, a key asset for Western defense and semiconductor supply chains. The community is actively discussing the stock's role in the critical minerals sector, focusing on the potential for government contracts and the impact of rising global tungsten demand on the company's long-term valuation.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

Market sentiment remains cautiously optimistic as investors balance solid earnings growth and AI-driven tech expansion against persistent geopolitical tensions in the Middle East and concerns over potential Federal Reserve rate adjustments. The community is actively debating the sustainability of high valuations versus long-term compounding, with many continuing to favor consistent dollar-cost averaging into broad-market index funds like VOO despite the ongoing macro uncertainty.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

Highest Performances Holdings (MAAS) is gaining momentum as investors pivot toward its strategy of deploying distributed AI computing and mobile energy infrastructure rather than focusing solely on legacy services. The stock is actively discussed by traders monitoring the company's ability to transition from conceptual AI announcements to tangible contract delivery, revenue collection, and the integration of sophisticated technology stacks into real-world enterprise projects.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as investors eagerly await the 80th trial event, which will trigger data unblinding for the Phase 3 REGAL trial. The community is actively debating the significance of the trial's extended timeline and institutional accumulation, interpreting the delay as a sign of potential efficacy for their GPS treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire HAMBURG, Germany, Aug. 6, 2026 Collaboration combines Odyssey's disease...

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Equity

The Boston-based clinical-stage biopharmaceutical company raised $279 million through an upsized offering, issuing 15.5 million shares of its common stock.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

Odyssey Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ODTXOdyssey Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest ODTX News